During the @-week placebo-controlled study period , @ % and @ % of patients had adverse events ( AEs ) in groups @ and @ , respectively ; similar AE reporting rates were observed through week @ ( @ % and @ % ) and among the golimumab-treated patients through week @ ( @ % ) .